1 augustus 2022: Bron:  2022; 12: 902967. Published online 2022 Jun 8.

Hier een verslag van een case studie uit een fase II studie met totaal 603 deelnemende patienten waarvan bij 90 patiënten met uitgezaaide niet-kleincellige longkanker al een abstract beschikbaar is. In deze studie wordt onderzocht wat het effect is van de tyrosine kinase remmer Poziotinib. Deze patiënte bereikte in hele korte tijd (9 maanden) een complete remissie. Zelfs nadat ze drie maanden is gestopt wegens de bijwekringen. Een lagere dosering bij de hervatting zorgde al snel voor een gedeeltelijke remissie en in oktober 2021 werd een complete remissie gezien op de scans. Februari 2022 werd deze complete remissie bevestigd in nieuwe scan. 

Hier de vertaling van het abstract van de case studie omdat dit goed weergeeft hoe deze longkankerpatiënte extreem goed reageerde op dit medicijn. Abstract van de eerste 90 patiënten staat onderaan dit artikel. Veel patiënten bereikten een gedeeltelijke respons. 

Casusrapport: uitzonderlijke respons op poziotinib bij patiënt met gemetastaseerde niet-kleincellige longkanker met EGFR Exon 20-insertiemutatie

Van de verschillende tyrosinekinaseremmers (TKI's) van de volgende generatie die zijn getest tegen ongewone EFGR-veranderingen, is aangetoond dat poziotinib een krachtig middel is voor uitgezaaide niet-kleincellige longkanker (mNSCLC) met afwijkingen in HER2 exon 20, en goedkeuring door de FDA is gezocht in de eerder behandelde populatie. Poziotinib heeft ook activiteit aangetoond in mNSCLC met afwijkingen in EGFR-exon 20.

Hier rapporteren we het eerste gepubliceerde geval van een patiënt met mNSCLC met een EGFR-exon 20-insertiemutatie (EGFRex20ins) die een volledige respons (CR) bereikte onder behandeling met poziotinib als onderdeel van de ZENITH20-proef.
In januari 2021 werd bij een voormalige roker van 62-jarige vrouwelijke patiënt een recidief vastgesteld, na twee operaties en postoperatieve chemotherapie van mNSCLC, aan de lever en retroperitoneale knopen. Gezien de identificatie door Next Generation Sequencing (NGS) van de EGFRex20ins-mutatie, nam ze deel aan het ZENITH20-cohort 5-onderzoek, een multicenter fase 2-onderzoek gericht op het beoordelen van de werkzaamheid en veiligheid van poziotinib bij patiënten met EGFR- of HER2-exon 20-insertiemutaties.

Poziotinib als eerstelijns systemische therapie voor gemetastaseerde ziekte werd eind januari 2021 gestart en toegediend in de initiële dosering van 8 mg oraal tweemaal daags (BID). De meest voorkomende bijwerkingen vanaf het begin van de behandeling waren alopecia, maculaire huiduitslag, diarree, xerostomie en conjunctivitis. Vanwege deze bijwerkingen werd de behandeling met poziotinib gedurende de eerste 3 maanden stopgezet en in april 2021 verlaagd tot 6 mg oraal tweemaal daags.

Na de-escalatie van de dosis verbeterden de bijwerkingen en verdroeg de patiënt de behandeling beter zonder verdere onderbreking. Sinds de eerste herevaluatie (na 4 weken therapie) bleek de behandeling met poziotinib opmerkelijk effectief te zijn, met een partiële respons (PR) die vervolgens werd bevestigd in mei en juli 2021. Vervolgens bevestigde een CT-scan in oktober 2021 een CR, onderhouden met een goede tolerantie bij de laatste herevaluatie in februari 2022. De behandeling wordt nog steeds voortgezet met dezelfde dosering.

In dit geval was poziotinib een succesvol en goed verdragen eerstelijns behandelingsalternatief voor chemotherapie bij deze patiënt met EGFR-exon 20-insertie-gemuteerd mNSCLC.

Originele Engelstalige abstract: 
 2022; 12: 902967.
Published online 2022 Jun 8. doi: 10.3389/fonc.2022.902967
PMCID: PMC9215205
PMID: 35756673

Case Report: Exceptional Response to Poziotinib in Patient with Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutation

Arsela Prelaj, 1 , 2 Achille Bottiglieri,corresponding author 1 , * Gajanan Bhat, 3 Rocky Washington, 3 Giuseppina Calareso, 4 Gabriella Francesca Greco, 4 Roberto Ferrara, 1 Marta Brambilla, 1 Alessandro De Toma, 1 Mario Occhipinti, 1 Sara Manglaviti, 1 Alberto Soro, 5 Monica Ganzinelli, 1 Giuseppe Lo Russo, 1 and Claudia Proto 1
Author information Article notes Copyright and License information Disclaimer

Abstract

Among the several next-generation tyrosine kinase inhibitors (TKIs) tested against uncommon EFGR alterations, poziotinib has been demonstrated to be a powerful agent for metastatic non-small-cell lung cancer (mNSCLC) with aberrations in HER2 exon 20, and FDA approval is being sought in the previously-treated population. Poziotinib has also shown activity in mNSCLC with aberrations in EGFR exon 20. Herein, we report the first published case of a patient affected by mNSCLC harbouring an EGFR exon 20 insertion (EGFRex20ins) mutation who achieved a complete response (CR) under treatment with poziotinib as part of the ZENITH20 trial. In January 2021, a former smoker 62-year-old female patient was diagnosed with relapse, after two surgeries and post-operative chemotherapy of mNSCLC, at liver and retroperitoneal nodes. Given the identification by Next Generation Sequencing (NGS) of EGFRex20ins mutation, she was enrolled in ZENITH20-cohort 5 trial, a phase 2 multicentre study aimed to assess the efficacy and safety of poziotinib in patients with EGFR or HER2 exon 20 insertion mutations. Poziotinib as first-line systemic therapy for metastatic disease was initiated at the end of January 2021 and administrated at the initial dosage of 8 mg orally twice daily (BID). The most common side effects from the beginning of the treatment included alopecia, macular skin rash, diarrhoea, xerostomia, and conjunctivitis. Due to these adverse events, poziotinib was discontinued during the first 3 months and then reduced to 6 mg orally BID in April 2021. After the dose de-escalation, the adverse events ameliorated, and the patient better tolerated the treatment without further interruption. Since the first reevaluation (after 4 weeks of therapy), the treatment with poziotinib resulted to be remarkably effective, with a partial response (PR) subsequently confirmed in May and July 2021. Then, in October 2021, a CT scan confirmed a CR, maintained with good tolerance at the last reevaluation in February 2022. Treatment is still ongoing at the same dosage. In this case, poziotinib has represented a successful and well-tolerated first-line treatment alternative to chemotherapy in this patient with EGFR exon 20 insertion mutated mNSCLC.


Poziotinib demonstrates antitumor activity in previously treated patients with HER2 exon 20 insertion NSCLC.

Clinical Trial
 
. 2022 Mar 1;40(7):710-718.
 doi: 10.1200/JCO.21.01323. Epub 2021 Nov 29.

Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial

Xiuning Le 1, Robin Cornelissen 2, Marina Garassino 3, Jeffrey M Clarke 4, Nishan Tchekmedyian 5, Jonathan W Goldman 6, Szu-Yun Leu 7, Gajanan Bhat 7, Francois Lebel 7, John V Heymach 1, Mark A Socinski 8
Affiliations 

Abstract

Purpose: Insertion mutations in Erb-b2 receptor tyrosine kinase 2 gene (ERBB2 or HER2) exon 20 occur in 2%-5% of non-small-cell lung cancers (NSCLCs) and function as an oncogenic driver. Poziotinib, a tyrosine kinase inhibitor, was evaluated in previously treated patients with NSCLC with HER2 exon 20 insertions.

Methods: ZENITH20, a multicenter, multicohort, open-label phase II study, evaluated poziotinib in patients with advanced or metastatic NSCLC. In cohort 2, patients received poziotinib (16 mg) once daily. The primary end point was objective response rate evaluated by independent review committee (RECIST v1.1); secondary outcome measures were disease control rate, duration of response, progression-free survival, and safety and tolerability. Quality of life was assessed.

Results: Between October 2017 and March 2021, 90 patients with a median of two prior lines of therapy (range, 1-6) were treated. With a median follow-up of 9.0 months, objective response rate was 27.8% (95% CI, 18.9 to 38.2); 25 of 90 patients achieved a partial response. Disease control rate was 70.0% (95% CI, 59.4 to 79.2). Most patients (74%) had tumor reduction (median reduction 22%). Median progression-free survival was 5.5 months (95% CI, 3.9 to 5.8); median duration of response was 5.1 months (95% CI, 4.2 to 5.5). Clinical benefit was seen regardless of lines and types of prior therapy, presence of central nervous system metastasis, and types of HER2 mutations. Grade 3 or higher treatment-related adverse events included rash (48.9%), diarrhea (25.6%), and stomatitis (24.4%). Most patients had poziotinib dose reductions (76.7%), with median relative dose intensity of 71.5%. Permanent treatment discontinuation because of treatment-related adverse events occurred in 13.3% of patients.

Conclusion: Poziotinib demonstrates antitumor activity in previously treated patients with HER2 exon 20 insertion NSCLC.

Trial registration: ClinicalTrials.gov NCT03318939.

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Subramanian J, Katta A, Masood A, et al. : Emergence of ERBB2 mutation as a biomarker and an actionable target in solid cancers. Oncologist 24:e1303-e1314, 2019 - PMC - PubMed
    1. Lee JW, Soung YH, Seo SH, et al. : Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin Cancer Res 12:57-61, 2006 - PubMed
    1. Takeda M, Sakai K, Hayashi H, et al. : Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2. Oncotarget 9:21132-21140, 2018 - PMC - PubMed
    1. Mazières J, Peters S, Lepage B, et al. : Lung cancer that harbors an HER2 mutation: Epidemiologic characteristics and therapeutic perspectives. J Clin Oncol 31:1997-2003, 2013 - PubMed
    1. Mazières J, Barlesi F, Filleron T, et al. : Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: Results from the European EUHER2 cohort. Ann Oncol 27:281-286, 2016 - PubMed
    1. Cha MY, Lee KO, Kim M, et al. : Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models. Int J Cancer 130:2445-2454, 2012 - PubMed
    1. Kang MH, Moon SU, Sung JH, et al. : Antitumor activity of HM781-36B, alone or in combination with chemotherapeutic agents, in colorectal cancer cells. Cancer Res Treat 48:355-364, 2016 - PMC - PubMed
    1. Kim HJ, Kim HP, Yoon YK, et al. : Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells. Anticancer Drugs 23:288-297, 2012 - PubMed
    1. Nam HJ, Kim HP, Yoon YK, et al. : Antitumor activity of HM781-36B, an irreversible pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer. Cancer Lett 302:155-165, 2011 - PubMed
    1. Robichaux JP, Elamin YY, Tan Z, et al. : Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med 24:638-646, 2018 - PMC - PubMed
    1. Robichaux JP, Elamin YY, Vijayan RSK, et al. : Pan-cancer landscape and analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity. Cancer Cell 36:444-457.e7, 2019 - PMC - PubMed
    1. Yasuda H, Kobayashi S, Costa DB: EGFR exon 20 insertion mutations in non-small-cell lung cancer: Preclinical data and clinical implications. Lancet Oncol 13:e23-31, 2012 - PubMed
    1. Koga T, Kobayashi Y, Tomizawa K, et al. : Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study. Lung Cancer 126:72-79, 2018 - PubMed
    1. Kim TM, Lee KW, Oh DY, et al. : Phase 1 studies of poziotinib, an irreversible pan-HER tyrosine kinase inhibitor in patients with advanced solid tumors. Cancer Res Treat 50:835-842, 2018 - PMC - PubMed
    1. Heymach J, Negrao M, Robichaux J, et al. : A phase II trial of poziotinib in EGFR and HER2 exon 20 mutant non-small cell lung cancer (NSCLC). J Thorac Oncol 13:S323-S324, 2018. (abstr OA02.06)
    1. Aaronson NK, Ahmedzai S, Bergman B, et al. : The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993 - PubMed
    1. Bergman B, Aaronson NK, Ahmedzai S, et al. : The EORTC QLQ-LC13: A modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer 30A:635-642, 1994 - PubMed
    1. De Grève J, Teugels E, Geers C, et al. : Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer 76:123-127, 2012 - PubMed
    1. Dziadziuszko R, Smit EF, Dafni U, et al. : Afatinib in NSCLC with HER2 mutations: Results of the prospective, open-label phase II NICHE trial of European Thoracic Oncology Platform (ETOP). J Thorac Oncol 14:1086-1094, 2019 - PubMed
    1. Kris MG, Camidge DR, Giaccone G, et al. : Targeting HER2 aberrations as actionable drivers in lung cancers: Phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. Ann Oncol 26:1421-1427, 2015 - PMC - PubMed
    1. Hyman DM, Piha-Paul SA, Won H, et al. : HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 554:189-194, 2018 - PMC - PubMed
    1. Zhou C, Li X, Wang Q, et al. : Pyrotinib in HER2-mutant advanced lung adenocarcinoma after platinum-based chemotherapy: A multicenter, open-label, single-arm, phase II study. J Clin Oncol 38:2753-2761, 2020 - PubMed
    1. Li BT, Shen R, Buonocore D, et al. : Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: Results from a phase II basket trial. J Clin Oncol 36:2532-2537, 2018 - PMC - PubMed
    1. Smit EF, Nakagawa K, Nagasaka M, et al. : Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01. J Clin Oncol 38, 2020. (suppl 15; abstr 9504)
    1. Connell CM, Doherty GJ: Activating HER2 mutations as emerging targets in multiple solid cancers. ESMO Open 2:e000279, 2017 - PMC - PubMed
    1. Wang Y, Jiang T, Qin Z, et al. : HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib. Ann Oncol 30:447-455, 2019 - PMC - PubMed
    1. Wang SE, Narasanna A, Perez-Torres M, et al. : HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 10:25-38, 2006 - PubMed
    1. Shigematsu H, Takahashi T, Nomura M, et al. : Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 65:1642-1646, 2005 - PubMed
    1. Kosaka T, Tanizaki J, Paranal RM, et al. : Response heterogeneity of EGFR and HER2 exon 20 insertions to covalent EGFR and HER2 inhibitors. Cancer Res 77:2712-2721, 2017 - PMC - PubMed
    1. Zhao S, Fang W, Pan H, et al. : Conformational landscapes of HER2 exon 20 insertions explain their sensitivity to kinase inhibitors in lung adenocarcinoma. J Thorac Oncol 15:962-972, 2020 - PubMed
    1. Fang W, Zhao S, Liang Y, et al. : Mutation variants and co-mutations as genomic modifiers of response to afatinib in HER2-mutant lung adenocarcinoma. Oncologist 25:e545-e554, 2020 - PMC - PubMed
    1. Zhang X, Lv J, Wu Y, et al. : HER2 exon 20 insertion mutations in lung adenocarcinoma: Case series and response to pyrotinib. Front Oncol 10:1162, 2020 - PMC - PubMed
    1. Nayak L, Lee EQ, Wen PY: Epidemiology of brain metastases. Curr Oncol Rep 14:48-54, 2012 - PubMed
    1. Waqar SN, Samson PP, Robinson CG, et al. : Non-small-cell lung cancer with brain metastasis at presentation. Clin Lung Cancer 19:e373-e379, 2018 - PMC - PubMed
    1. Offin M, Feldman D, Ni A, et al. : Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancers. Cancer 125:4380-4387, 2019 - PMC - PubMed
    1. Wu YL, Cheng Y, Zhou X, et al. : Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): A randomised, open-label, phase 3 trial. Lancet Oncol 18:1454-1466, 2017 - PubMed
    1. Park K, Tan EH, O'Byrne K, et al. : Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase 2B, open-label, randomised controlled trial. Lancet Oncol 17:577-589, 2016 - PubMed
    1. Le X, Shum E, Suga JM, et al. : Poziotinib administered twice daily improves safety and tolerability in patients with EGFR or HER2 exon 20 mutant NSCLC(ZENITH20-5) . Presented at the 112th Annual Meeting of the American Association for Cancer Research, Philadelphia, PA, April 10-15, 2021

Poziotinib, niet-kleincellige longkanker, TKR remmers, complete remissie, EGFR Exon 20 mutatie, ZENITH20-2 Trial


Plaats een reactie ...

Reageer op "Poziotinib geeft complete respons bij zwaar voorbehandelde patiënt met uitgezaaide niet kleincellige longkanker met EGFR Exon 20 mutatie. Veel andere patienten reageerden ook goed op Poziotinib"


Gerelateerde artikelen
 

Gerelateerde artikelen

Tyrosine Kinase Remmers (TKR) >> Afatinib, een Tyrosine kinase >> Alectinib geeft uitstekende >> Amivantamab + lazertinib samen >> Crizotinib is superieur aan >> Ensartinib geeft nog betere >> Osimertinib aanvullend op >> Poziotinib geeft complete >> Sotorasib verbetert ziekteprogressievrije >> Tyrosine Kinase remmers (TKI) >>